APA (7th ed.) Citation

Coleman, N., Stephen, B., Fu, S., Karp, D., Subbiah, V., Ahnert, J. R., . . . Naing, A. (2024). Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors. Cancer Medicine, 13(3), 1. https://doi.org/10.1002/cam4.6877

Chicago Style (17th ed.) Citation

Coleman, Niamh, et al. "Phase I Study of Sapanisertib (CB‐228/TAK‐228/MLN0128) in Combination with Ziv‐aflibercept in Patients with Advanced Solid Tumors." Cancer Medicine 13, no. 3 (2024): 1. https://doi.org/10.1002/cam4.6877.

MLA (9th ed.) Citation

Coleman, Niamh, et al. "Phase I Study of Sapanisertib (CB‐228/TAK‐228/MLN0128) in Combination with Ziv‐aflibercept in Patients with Advanced Solid Tumors." Cancer Medicine, vol. 13, no. 3, 2024, p. 1, https://doi.org/10.1002/cam4.6877.